Glabellar Lines

22 drugs in development·7 companies·10 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
dysport	NEXIEN BIOPHARMA, INC. (NXEN)
jeuveau	Evolus, Inc. (EOLS)

Phase 3(4)

Drug	Company
AGN-151586	AbbVie Inc. (ABBV)
Botox® 100 Units	ANI PHARMACEUTICALS INC (ANIP)
DWP712 inj.	ANI PHARMACEUTICALS INC (ANIP)
OnabotulinumtoxinA	AbbVie Inc. (ABBV)

Phase 2(9)

Drug	Company
formulation a	Allergan plc (AGN)
Formulation A	Revance Therapeutics, Inc. (RVNC)
formulation b	Allergan plc (AGN)
Formulation B	Revance Therapeutics, Inc. (RVNC)
formulation c	Allergan plc (AGN)
Formulation C	Revance Therapeutics, Inc. (RVNC)
onabotulinumtoxina x	Allergan plc (AGN)
Vehicle Control	Revance Therapeutics, Inc. (RVNC)
YY003	Revance Therapeutics, Inc. (RVNC)

Phase 1(1)

Drug	Company
JHM03	Revance Therapeutics, Inc. (RVNC)

Unknown(2)

Drug	Company
Letybo®	Revance Therapeutics, Inc. (RVNC)
Letybo®	ENANTA PHARMACEUTICALS INC (ENTA)

Phase 4(4)

Drug	Company
Abobotulinumtoxin A	Revance Therapeutics, Inc. (RVNC)
AbobotulinumtoxinA	Revance Therapeutics, Inc. (RVNC)
JTM201	Revance Therapeutics, Inc. (RVNC)
Rcombinant botulinum toxin type A for injection（Eveotox)	Revance Therapeutics, Inc. (RVNC)

BioSniper tracks 22 drugs in development for Glabellar Lines across 7 companies.

There are 10 clinical trials targeting Glabellar Lines tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.